{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-058638","form_type":"8-K","ticker":"AVBP","cik":"0001868279","company_name":"ArriVent BioPharma, Inc.","filed_at":"2026-05-11T20:05:49+00:00","discovered_at":"2026-05-11T20:08:00.325450+00:00","generated_at":"2026-05-11T22:45:23.688055+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ArriVent Q1 net loss $43.3M; cash $326.4M; Phase 3 firmonertinib data mid-2026","bullets":["Net loss of $43.3M for Q1 2026 versus $64.4M in Q1 2025; R&D expenses $37.6M (down 39% YoY).","Cash and investments $326.4M as of March 31, 2026, expected to fund operations into 4Q 2027.","Topline Phase 3 FURVENT data for firmonertinib in first-line EGFR exon 20 insertion NSCLC expected mid-2026.","FDA IND clearance for ARR-002 (MUC16/NaPi2b dual-target tetravalent ADC) for ovarian/endometrial cancers; first patient dosing in 2H 2026.","ARR-217 (CDH17 ADC) first patient dosed March 2026; dose escalation ongoing for gastrointestinal malignancies."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-058638","json":"https://secwatch.observer/filing/0001104659-26-058638.json","markdown":"https://secwatch.observer/filing/0001104659-26-058638.md","text":"https://secwatch.observer/filing/0001104659-26-058638.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1868279/000110465926058638/0001104659-26-058638-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1868279/000110465926058638/avbp-20260511x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T22:45:23.688055+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a94dbacb49e6f238ff13526574d537c7fbb11fde","claim":"ArriVent BioPharma, Inc. reported first quarter ended March 31, 2026 results: net income Net loss was $43.3 million and $64.4 million for the three months ended March 31, 2026 and 2025, respectively..","evidence_excerpt":"Net loss was $43.3 million and $64.4 million for the three months ended March 31, 2026 and 2025, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1868279/000110465926058638/0001104659-26-058638-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Net income","value":"Net loss was $43.3 million and $64.4 million for the three months ended March 31, 2026 and 2025, respectively."},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}